- Home
- CPBI vs PMVP Comparison
CPBI vs PMVP Comparison
Compare CPBI & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | PMVP |
|---|---|---|
| Founded | 2023 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 79.5M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPBI | PMVP |
|---|---|---|
| Price | $17.50 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.2K | ★ 397.9K |
| Earning Date | 06-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.00 | $0.82 |
| 52 Week High | $17.89 | $1.88 |
Technical Indicators
Market Signals| Indicator | CPBI | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 46.74 |
| Support Level | $17.37 | $1.26 |
| Resistance Level | $17.88 | $1.50 |
| Average True Range (ATR) | 0.32 | 0.06 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 50.00 | 33.33 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.